Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifurquinazol SCHEMBL28266163 | 0.89 | POLB (0.40) | POLBMMP2MMP9MMP8MMP13 | |
| Nifurquinazol SCHEMBL28198699 | 0.84 | KMT2A (0.44) | POLBMMP2MMP9MMP8MMP13 | |
| Nifurquinazol SCHEMBL28121681 | 0.84 | POLB (0.37) | POLBMMP2MMP9MMP8MMP13 | |
| SCHEMBL11839731 | 0.81 | ADORA2A (0.37) | POLBMMP2MMP9MMP8MMP13 | |
| SCHEMBL11670692 | 0.72 | POLB (0.48) | POLBMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL11881904 | 0.71 | NSD2 (0.33) | HTT | |
| SCHEMBL11814396 | 0.70 | MEN1 (0.65) | POLBMEN1KMT2AMAPTABCG2 | |
| SCHEMBL11848448 | 0.70 | TDP1 (0.39) | MMP2MMP9MMP8MMP13ALDH1A1 | |
| SCHEMBL1083959 | 0.70 | MAPT (0.55) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL11844928 | 0.68 | ADORA2A (0.38) | POLBMMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222066-A1 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| EP-4547023-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | University of Utah Research Foundation (US) | 2025-05-07 | — | — | EP | claimed |
| WO-2024085926-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-04-25 | — | — | WO | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| US-20210330645-A1 | ANTIBACTERIAL COMBINATIONS | MASSEY UNIVERSITY (NZ) | 2021-10-28 | — | — | US | claimed |
| EP-3746073-A1 | COMPOSITIONS FOR TREATING INFECTIVE ARTERIAL DISEASES AND RELATED CONDITIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2020-12-09 | — | — | EP | claimed |
| US-20200276362-A1 | COMPOSITION AND METHOD FOR CONTROLLED DRUG RELEASE FROM A TISSUE | BARD SHANNON LIMITED (US) | 2020-09-03 | — | — | US | claimed |
| EP-3687560-A1 | COMPOSITION AND METHOD FOR CONTROLLED DRUG RELEASE FROM A TISSUE | Bard Shannon Limited (PR) | 2020-08-05 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | POLB 2061/4885MMP2 3829/4885MMP9 2798/4885 |
| US-20200276362-A1 | COMPOSITION AND METHOD FOR CONTROLLED DRUG RELEASE FROM A TISSUE | PLOD3, TNNC1, S100A6 | POLB 4536/4885MMP2 374/4885MMP9 849/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | POLB 369/4885MMP2 2949/4885MMP9 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.